Status:
TERMINATED
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Siemens Corporation, Corporate Technology
GE Healthcare
Conditions:
Neuroendocrine Tumors
Brain (Nervous System) Cancers
Eligibility:
All Genders
18+ years
Brief Summary
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether ...
Eligibility Criteria
Inclusion
- 1.1 Patients with suspected or biopsy-proven liver masses including unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment.
- 1.2 Patients who have undergone prior chemotherapy more than one year prior to the study are eligible for enrollment.
- 1.4 Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.
- 1.5 No life expectancy restrictions.
- 1.6 ECOG and Karnofsky Performance Status will not be employed.
- 1.7 Patients with renal failure are ineligible for this study (Glomerular filtration rate (GFR) must be \> 60)
- 1.8 Ability to understand and willingness to sign a written informed consent document.
Exclusion
- 2.1 Patients who have undergone prior chemoembolization of hepatocellular carcinoma (HCC) are ineligible for enrollment. Patients who have undergone chemotherapy within one year prior to the study are also ineligible for enrollment.
- 2.2 No restrictions regarding use of other investigational agents.
- 2.3 Patients with severe contrast allergy are ineligible.
- 2.4 Patients who are pregnant or are trying to become pregnant are excluded from this study.
- 2.5 Patients who are cancer survivors or Human Immunodeficiency Virus (HIV)-positive will not be excluded.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01163526
Start Date
September 1 2010
End Date
July 1 2016
Last Update
January 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305